BUZZ-Biohaven provides update for its inflammatory disease drug; stock falls

Reuters04-16

** Drug developer Biohaven's shares fall 12.9% to $46.24

** Company provides update on ongoing early stage study of its experimental inflammatory disease drug called BHV-1300

** TD Cowen analyst Tyler Van Buren says the drug's starting dose of 10 milligrams is lower than anticipated

** Higher doses than what is being tested in first two cohorts will be required to achieve reductions of 70% or higher in levels of disease causing antibodies called IgG - Buren

** Drug showed IgG reductions of about 80%, seen about two days after a single dose, company says

** BTIG analyst Thomas Shrader says most troublesome issue with BHV-1300 is 5 gram to 20 gram equivalent doses

** "If these doses are required going forward, toxicity readouts will be of great interest" - Shrader

** Drug is safe and well tolerated with no serious adverse events reported, company says

** Including session moves, stock up 5% YTD

(Reporting by Sneha S K in Bengaluru)

((Sneha.SK@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment